Medical and Health Science Journal

  Previous Article | Back to Volume | Next Article
  Abstract | References | Citation | Download | Preview | Statistics
Volume 9
Issue 5
Online publication date 2011-11-05
Title Evaluation of hsCRP, F2-Isoprostane and homocysteine levels in patients presenting with Primary Hypercholesterolemia in a tertiary referral teaching hospital
Author T Rahman, YY Chew, SP Chan, S Muid
Novel cardiac markers are the cornerstone of cardiovascular risk factors.  It has been well established that plasma homocysteine (Hcys), plasma 8-isoprostane and serum high sensitive C-reactive protein (hsCRP) are newer biomarkers of cardiovascular risk and are strong predictors of cardiac events.
The purpose of this study was to investigate the levels of these newer biomarkers of cardiovascular risk in patients with familial hypercholesterolaemia (FH) and compare them to those of age and gender matched normolipaemic control group.
We conducted a cross-sectional study to investigate the levels of these biomarkers in primary hypercholesterolaemic patients. Fifty six primary hypercholesterolaemic patients, 29 familial hypercholesterolaemia (FH) and 27 non familial hypercholesterolaemia (NFH) age and gender matched control subjects were recruited for this study. Blood samples were taken for the analysis of serum fasting lipid profile, serum hsCRP, plasma Hcys and plasma 8-isoprostane.
Serum Hcys levels were higher in all patients compared with control (mean SD: 11.3 6.4 vs 8.6 3.3, p<0.05) with Hcys values being significantly higher in NFH group (mean SD: 11.9 7.0 vs 8.6 3.3, p<0.05) compared with control.  Serum hs-CRP were higher in NFH group (p<0.05) compared to control.  Plasma 8-isoprostane levels of the primary hypercholesterolaemic patients were higher (mean SEM: 1357.0 214.7 vs 398.0 20.5, p<0.05) compared to control and they were also higher in FH and NFH subgroups compared to control (mean SEM: 1395.8 313.3 vs 398.0 20.5, p<0.05 and 1322.8 300.7 respectively).  A significant correlation was seen between serum total cholesterol with serum Hcys and plasma isoprostane (r=0.6, p<0.001 and r=0.5, p<0.001 respectively).  Correlation was also noted between serum LDL-c with serum Hcys (r=0.6, p<0.001) and plasma 8-isoprostane (r=0.5, p<0.05
In summary, this study has demonstrated that there is an significant association between hypercholesterolaemia with serum hsCRP, Hcys and plasma 8-isoprostane levels.
Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflamma-tion/CRP evaluation (PRINCE): a randomized trial and cohort study. J Am Med Assoc 2001; Vol.286, pp.64-70  

Chaturvedi, N, McKeigue, PM, Marmot, MG., 1994. “Relationship of glucose intolerance to coronary risk in Afro-Caribbeans compared with Europeans,” Diabetologia, Vol.37, pp.765-72
Davi G, Falco A, Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipids. 2004; Vol.128, pp.149-63

Famm SS, Morrow JD. The isoprostanes: Unique products of arachidonic acid oxidation—a review. Curr Med Chem. 2003; Vol.10, pp.1723-740

Fruchart, JC, Nierman, MC, Stroes, ESG, Kastelein, JJP, Duriez, P., 2004. “New risk factors for atherosclerosis and patient risk assessment,” Circulation, Vol.109, pp.15-19

Heller, RF, Chinn, S, Pedoe, HD, Rose, G., 1984. “How well can we predict coronary heart disease? Findings in the United Kingdom Heart Disease Prevention Project,” BMJ, Vol.288, pp.1409-411

Khot, UN, Khot, MB, Bajzer, CT et al., 2003. “Prevalence of conventional risk factors in patients with coronary heart disease,” JAMA, Vol.290, pp.898-904

Kullo, IJ, Gau, GT, Tajik, AJ., 2000. “Novel risk factors for atherosclerosis,” Mayo Clinic Proceedings, Vol.75(4), pp.369-80

Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; Vol.103, pp.1933-35

Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 2001; Vol.77, pp.247-53

Ridker, PM, Brown, NJ, Vaughan, DE, Harrison, DG, Mehta, JL., 2004. “Established and emerging plasma biomarkers in the prediction of first atherothrombotic events,” Circulation, Vol.109, pp.6-19

Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; Vol.100, pp.230-35

Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; Vol.103, pp.1191-3

Ridker, PM, Rifai, N, Rose, L et al., 2002. “Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events,” N Engl J Med., Vol.347, pp.1557-565

Roberts LJ, Morrow JD. Measurement of F2-isoprostanes an index of oxidative stress in vivo. Free Radic Biol Med. 2000; Vol.28, pp.505-13

Rokach J, Khanapure SP, Hwang SW, Adiyaman M, Lawson JA, FitzGerald GA. The isoprostanes: A perspective. Prostaglandins. 1997; Vol.54, pp.823-51

Wald, NJ, Law, M, Watt, HC et al., 1994. “Apolipoproteins and ischaemic heart disease; implications for screening,” Lancet, Vol.343, pp.75-79

Yao, C, Wu, Z, Wu, Y., 1993. “The changing pattern of cardiovascular diseases in China,” World Health Stat Q., Vol.46, pp.113-18
Keywords hs-CRP, homocysteine, 8-isoprostane, familial hypercholesterolaemia
Pages 9-17
Download Full PDF Download
  Previous Article | Back to Volume | Next Article
Search in articles
Journal Published articles
MHSJ 940
Journal Hits
MHSJ 2561956
Journal Downloads
MHSJ 17477
Total users online -